Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
Organogenesis (Nasdaq: ORGO) will report fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Organogenesis (Nasdaq: ORGO) will report fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 26, 2026.
Management will host a conference call and live webcast at 5:00 p.m. ET on February 26 to discuss results and provide a corporate update; the webcast will be archived on the company website for about one year.
Details
News Market Reaction – ORGO
On Feb 20, the first trading day after this news, ORGO closed 0.25% above the previous close.
Data tracked by StockTitan Argus for the Feb 20 session.
Key Figures
- Earnings date
- February 26, 2026
- Scheduled Q4 and FY2025 results release after market close
- Conference call time
- 5:00 p.m. Eastern Time
- Time for Q4 and FY2025 results conference call
- Webcast archive duration
- approximately one year
- Length of time earnings webcast will remain available online
Historical Context
-
Avista Healthcare Partners promoted investment team members tied to ORGO’s board.
-
Initiated rolling BLA submission to FDA for ReNu in knee osteoarthritis.
-
Reported successful FDA Type-B meeting and plan to begin rolling BLA for ReNu.
-
Posted record Q3 revenue, higher earnings, and raised FY2025 guidance.
-
Highlighted CMS payment reform seen as supportive for skin substitute products.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th.
Management will host a conference call at 5:00 p.m. Eastern Time on February 26th to discuss the results of the quarter and the fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
Investor Inquiries:
ICR Healthcare
Mike Piccinino, CFA
OrganoIR@icrinc.com
Press and Media Inquiries:
Organogenesis
communications@organo.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.